
|Videos|June 11, 2021
Secukinumab Approved for Plaque Psoriasis in Children, Adolescents
Author(s)Linda Stocum, Associate Editor
John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5


















